← Back to Search

Bevacizumab for Brain Cancer

Phase 1 & 2
Recruiting
Led By John Boockvar, MD
Research Sponsored by Northwell Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with a documented histologic diagnosis of relapsed or refractory glioblastoma multiforme (GBM), anaplastic astrocytoma (AA) or anaplastic mixed oligoastrocytoma (AOA)
Patients must have a Karnofsky performance status 70% (or the equivalent ECOG level of 0-2)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 month
Awards & highlights

Study Summary

This trial is testing if repeated doses of the drug bevacizumab, given through a catheter directly to the brain, are safe and effective in treating patients with recurrent brain tumors.

Who is the study for?
Adults with relapsed or refractory high-grade brain tumors like GBM and AA, who have not had more than two cycles of Bevacizumab treatment. Participants must be able to perform daily activities (Karnofsky performance status ≥70%), have at least one confirmed tumor site, and agree to use contraception during the study.Check my eligibility
What is being tested?
The trial is testing repeated doses of intraarterial Bevacizumab for safety and effectiveness in treating recurrent malignant glioma. It aims to see if this method improves survival compared to standard intravenous therapy by delivering the drug directly into arteries supplying the tumor.See study design
What are the potential side effects?
Bevacizumab can cause side effects such as bleeding, high blood pressure, wound healing complications, kidney problems, and may affect fertility. Since it's delivered directly to brain arteries in this trial, there might also be risks specific to that delivery method.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a confirmed diagnosis of a specific type of brain tumor that has returned or is not responding to treatment.
Select...
I am mostly independent and can care for myself.
Select...
I am 18 years old or older.
Select...
I have at least one tumor confirmed by biopsy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Composite overall response rate (CORR)
Progression-free survival (PFS) and overall survival (OS)
Secondary outcome measures
The safety of repeated SIACI of mannitol and Bevacizumab at 15mg/kg.

Side effects data

From 2015 Phase 4 trial • 45 Patients • NCT02036424
22%
vitreous hemorrhage
17%
worsening of cataract
9%
posterior capsule opacification
9%
vitreous syneresis
4%
cranial nerve VI palsy
4%
bradycardia
4%
pneumonia
4%
pyelonephritis
4%
colon cancer
100%
80%
60%
40%
20%
0%
Study treatment Arm
Bevacizumab
Ozurdex

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm 2Experimental Treatment1 Intervention
Group II: Arm 1Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bevacizumab
FDA approved

Find a Location

Who is running the clinical trial?

Feinstein Institute for Medical ResearchOTHER
21 Previous Clinical Trials
5,618 Total Patients Enrolled
Northwell HealthLead Sponsor
457 Previous Clinical Trials
470,205 Total Patients Enrolled
John Boockvar, MD3.916 ReviewsPrincipal Investigator - Feinstein Institute for Medical Research
Feinstein Institute for Medical Research
13 Previous Clinical Trials
771 Total Patients Enrolled
5Patient Review
This neurosurgeon is a true hero and miracle worker.

Media Library

Bevacizumab Clinical Trial Eligibility Overview. Trial Name: NCT01269853 — Phase 1 & 2
Anaplastic Astrocytoma Research Study Groups: Arm 2, Arm 1
Anaplastic Astrocytoma Clinical Trial 2023: Bevacizumab Highlights & Side Effects. Trial Name: NCT01269853 — Phase 1 & 2
Bevacizumab 2023 Treatment Timeline for Medical Study. Trial Name: NCT01269853 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open slots remaining for this clinical trial?

"That is correct. The listing on clinicaltrials.gov affirms that this study, which was first posted on 10/1/2010, is looking for new participants. A total of 54 patients will be enrolled at 1 site."

Answered by AI

How many individuals are being given this medication as part of the research?

"That is correct. The trial, which was first advertised on October 1st 2010 and has since been edited November 10th 2022, is still looking for patients. A total of 54 people are needed at a single site."

Answered by AI

What has Bevacizumab been traditionally used to alleviate?

"Bevacizumab is a medication used to treat cancer. More specifically, it has been shown to be effective in treating recurrent platinum sensitive primary peritoneal cancer, stage iv epithelial ovarian cancer following initial surgical resection, and locally advanced nonsquamous non-small cell lung cancer."

Answered by AI

What other investigational uses has Bevacizumab been trialed for?

"Currently, 375 clinical trials are underway to test the efficacy of bevacizumab. Of these, 99 are in Phase 3. Many of the bevacizumab trials are based in Taibei, Taiwan; however, there are a total of 18908 locations running studies for this treatment across the globe."

Answered by AI
~5 spots leftby Oct 2025